Precision radiation aims to tame scattered tumors
NCT ID NCT02933242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a precise type of radiation called SABR for people with a limited number of metastatic tumors (up to 5). The goal is to see how well patients tolerate the treatment and how it affects their quality of life and survival. About 399 participants will receive daily or every-other-day radiation over 1–3 weeks, with follow-up to track side effects and cancer control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic ablative body radiotherapy (SABR)
- What this could lead to
- If successful, this could show that precisely targeted radiation improves quality of life and controls limited metastases without major side effects.
- What could go wrong
- This is a non-randomized, single-arm study, so results may not prove SABR is better than standard care. Side effects depend on the organ treated and could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer
Prince George, British Columbia, V2M 7E9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.